866-997-4948(US-Canada Toll Free)

Global Liver Cirrhosis Market 2016-2020

Published By :

Technavio

Published Date : May 2016

Category :

Metabolic Disorders

No. of Pages : 74 Pages

About Cirrhosis of the Liver

Cirrhosis of the liver (or liver fibrosis) is a serious condition in which the liver stops functioning properly due to damage and irreversible scarring of the liver tissue. The scarring of the tissue is often caused by long-term exposure to viral infections and toxins such as alcohol. Chronic viral hepatitis and non-alcoholic steatohepatitis can also cause liver cirrhosis. Alcohol-related medications, antiviral medications, and metal chelating agents are used in the treatment of the causes of liver cirrhosis while antibiotics, vitamins, corticosteroids, diuretics, beta-blockers, and laxatives are used for the treatment of the complications of the disease.

Technavios analysts forecast the global liver cirrhosis therapeutics market to grow at a CAGR of 4.36% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global liver cirrhosis therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of prescription, generic, and off-label drugs used in the treatment of liver cirrhosis.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

Technavio's report, Global Liver Cirrhosis Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
F Hoffman La-Roche
GlaxoSmithKline
Gilead Sciences
Johnson & Johnson
Merck

Other prominent vendors
Bristol-Myers Squibb
Conatus Pharmaceuticals
Gwo Xi Stem Cell Applied Technology
Instituto Grifols
Intercept Pharmaceuticals
NGM Biopharmaceuticals
Norgine
Pharmicell
Salix Pharmaceuticals
Stempeutics Research

Market driver
High prevalence of liver cirrhosis
For a full, detailed list, view our report

Market challenge
Adverse effects of drugs
For a full, detailed list, view our report

Market trend
Use of off-label drugs
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Disease overview
Understanding the disease
Etiology
Symptoms
Pathophysiology
Diagnosis
Epidemiology
Prevention
Treatment
Impact of alcohol consumption on liver cirrhosis
PART 06: Pipeline portfolio
Information on pipeline candidates
Clinical trials for liver cirrhosis
PART 07: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 08: Market segmentation by type of molecule
Biologics
Small molecules
PART 09: Market segmentation by types of liver cirrhosis
PART 10: Market segmentation by types of liver cirrhosis treatment
Medications to treat causes of liver cirrhosis
Medications to treat complications of liver cirrhosis
PART 11: Geographical segmentation
Liver cirrhosis medication market in Americas
Market overview
Market size and forecast
Liver cirrhosis medication market in EMEA
Market overview
Market size and forecast
Liver cirrhosis medication market in APAC
Market overview
Market size and forecast
PART 12: Market drivers
High prevalence of liver cirrhosis
Advances in technology
High unmet medical needs
Changes in lifestyle
PART 13: Impact of drivers
PART 14: Market challenges
Use of alternative therapies
Adverse effects of drugs
Poor patient adherence
Stringent regulatory guidelines
PART 15: Impact of drivers and challenges
PART 16: Market trends
Rise in public awareness
Increase in R&D
Use of off-label drugs
Patient assistance programs
PART 17: Vendor landscape
Competitive scenario
F Hoffmann-La Roche
GlaxoSmithKline
Gilead Sciences
Johnson & Johnson
Merck
Other prominent vendors
PART 18: Appendix
List of abbreviations
PART 19: Explore Technavio
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Stages of liver diseases
Exhibit 03: Causes of liver cirrhosis
Exhibit 04: Diagnosis of liver cirrhosis
Exhibit 05: Effect of alcohol consumption on liver cirrhosis
Exhibit 06: Pipeline molecules for liver cirrhosis
Exhibit 07: Clinical trials by development phase
Exhibit 08: Clinical trials by trial status
Exhibit 09: Global liver cirrhosis medication market 2015-2020 ($ billions)
Exhibit 10: Five forces analysis
Exhibit 11: Four main types of liver cirrhosis
Exhibit 12: Market share by types of liver cirrhosis
Exhibit 13: Types of treatment for liver cirrhosis
Exhibit 14: Global liver cirrhosis medication market segment by geography 2015
Exhibit 15: Global liver cirrhosis medication market segment by geography 2015-2020 ($ millions)
Exhibit 16: Liver cirrhosis medication market in Americas ($ millions)
Exhibit 17: Liver cirrhosis medication market in EMEA ($ millions)
Exhibit 18: Liver cirrhosis medication market in APAC ($ billions)
Exhibit 19: Impact of drivers
Exhibit 20: Impact of drivers and challenges
Exhibit 21: F Hoffmann-La Roche: Business segmentation 2014 by revenue
Exhibit 22: F Hoffmann-La Roche: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 23: F Hoffmann-La Roche: Geographical segmentation by revenue 2014
Exhibit 24: F Hoffmann-La Roche: YoY growth and revenue of Pegasys 2012-2014 ($ billions)
Exhibit 25: F Hoffmann-La Roche: Key takeaways
Exhibit 26: GlaxoSmithKline: Business segmentation by revenue 2014
Exhibit 27: GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 28: GlaxoSmithKline: Geographical segmentation by revenue 2014
Exhibit 29: GlaxoSmithKline: YoY growth and revenue of Epivir 2012-2014 ($ millions)
Exhibit 30: Gilead Sciences: Geographical segmentation by revenue 2014
Exhibit 31: Gilead Sciences: YoY revenue comparison of Sovaldi 2013-2014 ($ millions)
Exhibit 32: Gilead Sciences: YoY growth and revenue of Viread 2012-2014 ($ millions)
Exhibit 33: Gilead Sciences: Key takeaways
Exhibit 34: Johnson & Johnson: Business segmentation by revenue 2014
Exhibit 35: Johnson & Johnson: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 36: Johnson & Johnson: Geographical segmentation by revenue 2014
Exhibit 37: Johnson & Johnson: YoY growth and revenue of Incivo 2012-2014 ($ millions)
Exhibit 38: Johnson & Johnson: YoY revenue growth of Olysio 2012-2014 ($ millions)
Exhibit 39: Johnson & Johnson: Key takeaways
Exhibit 40: Merck: Business segmentation by revenue 2014
Exhibit 41: Merck: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 42: Merck: Geographical segmentation by revenue 2014
Exhibit 43: Merck: YoY growth and revenue of PegIntron 2012-2014 ($ millions)
Exhibit 44: Merck: YoY growth and revenue of Victrelis 2012-2014 ($ millions)
Exhibit 45: Merck: Key takeaways

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *